ConductScience.org, home

TrialNCT04540887ClinicalTrials.gov

PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome

CompletedNot applicableResults posted 20 Jul 2022

NCT04540887, Not applicable, Completed, Wake Forest University Health Sciences; results first posted 2022-07-20

Cite this record

ConductScience Library. PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome. Trials, record NCT04540887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04540887

FollowSave as evidenceDownload JSON
Condition
Interstitial Cystitis152 trials
Condition
Bladder Pain Syndrome65 trials
Sources
3 sources
Release
trials-2026-11-12-0.5.0

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
NCT number
NCT04540887
Status
Completed
Phases
Not applicable
Enrollment
10 participants, actual
Lead sponsor
Wake Forest University Health Sciences
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Pulsed Electromagnetic Field (PEMF) Therapy
First posted
2020-09-07
Last updated
2022-12-05
Results first posted
2022-07-20
Limitations and caveats
The primary limitation of this pilot clinical trial was the small sample size and absence of a control group. We recognize the potential for a significant placebo effect among this patient population. Furthermore, our results are non-generalizable as we evaluated only females, and only those that were considered to have a non-bladder centric IC/BPS phenotype. To mitigate these shortcomings, the next iteration of this trial will employ a randomized, double-blind, sham-controlled study design.

Source ClinicalTrials.gov

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)

Primary · Baseline before beginning treatment · Mean · score on a scale · Standard Deviation

Show Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) as
Pulsed Electromagnetic Field Therapy (PEMF)6.700.675
GroupCategoryValueSpreadUnits
Pulsed Electromagnetic Field Therapy (PEMF)6.70Standard Deviation 0.675score on a scale

Change From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)

Primary · Week 12 · Mean · score on a scale · Standard Deviation

Show Change From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) as
Pulsed Electromagnetic Field Therapy (PEMF)4.181.462
Pulsed Electromagnetic Field Therapy (PEMF)5.341.845
GroupCategoryValueSpreadUnits
Pulsed Electromagnetic Field Therapy (PEMF)4.18Standard Deviation 1.462score on a scale
Pulsed Electromagnetic Field Therapy (PEMF)5.34Standard Deviation 1.845score on a scale

Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Problem Index (ICPI)

Secondary · Baseline before beginning treatment, Week 4, and Week 12 · Mean · scores on a scale · Standard Deviation

Show Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) as

Baseline

Pulsed Electromagnetic Field Therapy (PEMF)131.927

Week 4

Pulsed Electromagnetic Field Therapy (PEMF)9.1254.581

Week 12

Pulsed Electromagnetic Field Therapy (PEMF)10.753.742
GroupCategoryValueSpreadUnits
Pulsed Electromagnetic Field Therapy (PEMF)Baseline13Standard Deviation 1.927scores on a scale
Pulsed Electromagnetic Field Therapy (PEMF)Week 49.125Standard Deviation 4.581scores on a scale
Pulsed Electromagnetic Field Therapy (PEMF)Week 1210.75Standard Deviation 3.742scores on a scale

Change in IC/BPS Symptoms, as Measured by Wake Forest Baptist Health IC/BPS Global Response Assessment (GRA)

Secondary · Baseline, 4-weeks post-treatment, and 8-weeks post-treatment · Median · score on a scale · Inter-Quartile Range

Show Change in IC/BPS Symptoms, as Measured by Wake Forest Baptist Health IC/BPS Global Response Assessment (GRA) as

Baseline

Treatment00 to 0

4-weeks post-treatment

Treatment21 to 2

8-weeks post-treatment

Treatment21 to 3
GroupCategoryValueSpreadUnits
TreatmentBaseline0Inter-Quartile Range 0 to 0score on a scale
Treatment4-weeks post-treatment2Inter-Quartile Range 1 to 2score on a scale
Treatment8-weeks post-treatment2Inter-Quartile Range 1 to 3score on a scale

Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI)

Secondary · Baseline before beginning treatment, Week 4, and Week 12 · Mean · scores on a scale · Standard Deviation

Show Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) as

Baseline before beginning treatment

Treatment13.8752.949

Week 4

Treatment94.781

Week 12

Treatment103.741
GroupCategoryValueSpreadUnits
TreatmentBaseline before beginning treatment13.875Standard Deviation 2.949scores on a scale
TreatmentWeek 49Standard Deviation 4.781scores on a scale
TreatmentWeek 1210Standard Deviation 3.741scores on a scale

The charts draw each outcome whole in the first 20 of 24 rows.

Participant flow3

How many started, completed or left each group, period by period.

Participants by period and group

As posted, period by period

Show Participants by period and group as

Completed the periodDid not complete it

Overall Study

Pulsed Electromagnetic Field Therapy (PEMF)10 started8 completed2 did not
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDPulsed Electromagnetic Field Therapy (PEMF)10
Overall StudyCOMPLETEDPulsed Electromagnetic Field Therapy (PEMF)8
Overall StudyNOT COMPLETEDPulsed Electromagnetic Field Therapy (PEMF)2

Source ClinicalTrials.gov

Download CSV of participant flow

Adverse event totals3

The totals the trial posted for each group.

Participants affected

Share of the participants at risk

Show Participants affected as

Total, all-cause mortality

Pulsed Electromagnetic Field Therapy (PEMF)0 of 10

Total, other adverse events

Pulsed Electromagnetic Field Therapy (PEMF)0 of 10

Total, serious adverse events

Pulsed Electromagnetic Field Therapy (PEMF)0 of 10
TotalGroupAffectedAt risk
Total, all-cause mortalityPulsed Electromagnetic Field Therapy (PEMF)010
Total, other adverse eventsPulsed Electromagnetic Field Therapy (PEMF)010
Total, serious adverse eventsPulsed Electromagnetic Field Therapy (PEMF)010

Source ClinicalTrials.gov

Download CSV of adverse event totals

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryPelvic Pain, as Measured by the Numeric Rating Scale (NRS)Baseline before beginning treatment
The NRS evaluates average pain intensity. It appears as a horizontal line with an eleven-point range. The NRS is labeled from 0 to 10, with 0 indicating no pain and 10 indicating severe pain ("worst pain imaginable").
PrimaryChange From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)Week 4
The NRS evaluates average pain intensity. It appears as a horizontal line with an eleven-point range. The NRS is labeled from 0 to 10, with 0 indicating no pain and 10 indicating severe pain ("worst pain imaginable").
PrimaryChange From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)Week 12
The NRS evaluates average pain intensity. It appears as a horizontal line with an eleven-point range. The NRS is labeled from 0 to 10, with 0 indicating no pain and 10 indicating severe pain ("worst pain imaginable").
SecondaryChange in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Problem Index (ICPI)Baseline before beginning treatment, Week 4, and Week 12
The ICPI (score range: 0-16 points) contain four questions related to urinary and pain symptoms. For the problem index, all four questions utilize a range of 0-4 with 0 indicating it is no problem and 4 indicating it is a big problem. Higher scores indicate more severe symptoms and greater disease progression, while lower scores indicate less severe symptoms and less disease progression.
SecondaryChange in IC/BPS Symptoms, as Measured by Wake Forest Baptist Health IC/BPS Global Response Assessment (GRA)Baseline, 4-weeks post-treatment, and 8-weeks post-treatment
The GRA asks participants to list any in-office treatments, home treatments, medications, or procedures they have had in the past year for IC/BPS. Then, they are asked to score those treatments based on a seven point scale (-3 to +3) with -3 indicating their symptoms became markedly worse and +3 indicating their symptoms were markedly improved after treatment.
SecondaryChange in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI)Baseline before beginning treatment, Week 4, and Week 12
The ICSI (score range: 0-19 points) contains four questions related to urinary and pain symptoms. For the symptoms index, 3 of the 4 questions utilize a range of 0-5 with 0 indicated the symptom is never experienced and 5 indicating the symptom is almost always experienced. The fourth question utilizes a range of 0-4 with 0 indicating the symptom is never experienced and 4 indicating the symptom is almost always experienced. Higher scores indicate more severe symptoms and greater acuity of disease progression, while lower scores indicate less severe symptoms and lower acuity of disease progression.
SecondaryChange in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Void and Intake MeasurementsBaseline before beginning treatment and Week 4
Participants will be instructed on how to complete 3-day voiding diary prior to initial office visit and following assessments. The participant will use a new diary sheet for every 24-hour period. Data analysis will be measured based on urgency score, total urine volume (TUV) (mL), maximum voided volume (MVV) (mL), mean voided volume (mL), and fluid intake (mL). For TUV, MVV, and mean voided volume, higher voided volume (in mL) indicates more efficient bladder-emptying and less severe symptoms, while a lower voided volume (in mL) indicates less efficient bladder-emptying and more severe symptoms.
SecondaryChange in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Number of VoidsBaseline before beginning treatment and Week 4
Participants will be instructed on how to complete 3-day voiding diary prior to initial office visit and following assessments. The participant will use a new diary sheet for every 24-hour period with sections identifying time of day (with wake time and bed time indicated by participant), fluid intake (type of fluid ingested and amount in oz), urination (amount in oz voided into urinary hat or urinal), amount of urine drained via catheter if applicable, leaks (any time participant experienced involuntary urine loss indicated by a check mark in the corresponding time column) if applicable, and pad changes if applicable. Data analysis will be measured based on daily number of voids (voids). For number of voids specifically, a greater number of voids in a 24-hour period indicates increased urinary frequency and more severe symptoms, while a fewer number of voids in a 24-hour period indicates decreased urinary frequency and less severe symptoms.
SecondaryChange in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Urgency ScoreBaseline before beginning treatment and Week 4
Participants will be instructed on how to complete 3-day voiding diary prior to initial office visit and following assessments. The participant will use a new diary sheet for every 24-hour period with sections identifying time of day (with wake time and bed time indicated by participant), fluid intake (type of fluid ingested and amount in oz), urination (amount in oz voided into urinary hat or urinal), amount of urine drained via catheter if applicable, leaks (any time participant experienced involuntary urine loss indicated by a check mark in the corresponding time column) if applicable, and pad changes if applicable. Data analysis will be measured based on urgency score (scale: 0-3, with 0 indicating no urgency and 3 indicating maximum urgency). For the urgency score specifically, lower scores indicate less severe urinary symptoms/urgency while higher scores indicate more severe urinary symptoms/urgency.

Source ClinicalTrials.gov

Download CSV of registered outcomes

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYPelvic Pain, as Measured by the Numeric Rating Scale (NRS)Baseline before beginning treatmentscore on a scaleMEAN
PRIMARYChange From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)Week 4score on a scaleMEAN
PRIMARYChange From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)Week 12score on a scaleMEAN
SECONDARYChange in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Problem Index (ICPI)Baseline before beginning treatment, Week 4, and Week 12
Of 10 participants initially enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. These participants were included in the baseline data analysis but were excluded from the 4- and 8-week post-enrollment data analysis.
scores on a scaleMEAN
SECONDARYChange in IC/BPS Symptoms, as Measured by Wake Forest Baptist Health IC/BPS Global Response Assessment (GRA)Baseline, 4-weeks post-treatment, and 8-weeks post-treatment
Of 10 participants initially enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. These participants were included in the baseline data analysis but were excluded from the 4- and 8-week post-enrollment data analysis. Additionally, 1 patient at the 4-week post-treatment evaluation and 3 patients in the 8-week post-treatment evaluation did not specifically list PEMF therapy in the GRA, and therefore their data were excluded from analysis.
score on a scaleMEDIAN
SECONDARYChange in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI)Baseline before beginning treatment, Week 4, and Week 12
Of 10 participants initially enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. These participants were included in the baseline data analysis but were excluded from Week 4 and Week 12 data analysis.
scores on a scaleMEAN
SECONDARYChange in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Void and Intake MeasurementsBaseline before beginning treatment and Week 4
Of 10 participants enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. Their data was excluded from data analysis. Additionally, of the remaining 8 participants, 2 failed to complete their voiding diaries in its entirety and one additional participant did not complete her fluid intake. Thus, 6 women had evaluable voiding information and 5 had data for fluid intake to evaluate.
mLMEAN
SECONDARYChange in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Number of VoidsBaseline before beginning treatment and Week 4
Of 10 participants enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. Their data was excluded from data analysis. Additionally, of the remaining 8 participants, 2 failed to complete their voiding diaries in its entirety.
voidsMEAN
SECONDARYChange in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Urgency ScoreBaseline before beginning treatment and Week 4
Of 10 participants enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. Their data was excluded from data analysis. Additionally, of the remaining 8 participants, 2 failed to complete their voiding diaries in its entirety.
Score on a scaleMEAN

Source ClinicalTrials.gov

Download CSV of outcomes

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource
2107633BACKGROUNDPubMed
17900797BACKGROUNDPubMed
21176078BACKGROUNDPubMed
24900993BACKGROUNDPubMed
29264207BACKGROUNDPubMed

Download CSV of papers

Data dates

The day ClinicalTrials.gov processed this copy's newest data, and the day each source was copied for this release.

Processed by ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

None in this release

  • Adverse events
  • Grants
  • Trial comparisons
  • Tests

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04540887

GET https://conductscience.org/api/trials/v1/NCT04540887/results?page=2